NICM
ITCI

Neo Ivy Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Neo Ivy Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-872
Closed -$45K – 478
2023
Q3 		$45K Buy
+872
New +$50.8K 0.02% 279
2021
Q3 		– Sell
-3,421
Closed -$140K – 658
2021
Q2 		$140K Buy
+3,421
New +$126K 0.14% 225
2021
Q1 		– Sell
-3,495
Closed -$111K – 643
2020
Q4 		$111K Buy
3,495
+2,623
+301% +$68.9K 0.12% 245
2020
Q3 		$22K Buy
+872
New +$19.9K 0.02% 412

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neo Ivy Capital Management's ITCI Position: Q4 2023 in Review

Neo Ivy Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2023, closing a stake of 872 shares — an estimated $45K sold.

Neo Ivy Capital Management first reported a position in ITCI in Q3 2020 and held it in 4 quarters. The position peaked at $140K in Q2 2021. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Neo Ivy Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2023 after selling out during the quarter.
  • Neo Ivy Capital Management sold 872 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $45K.
  • Neo Ivy Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 4 quarters.
  • Neo Ivy Capital Management's Intra-Cellular Therapies Inc. position peaked at $140K in Q2 2021.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Neo Ivy Capital Management's 13F filing for Q4 2023, filed 26 Feb 2024.